Sigilon Therapeutics Raises $80.3M in Series B Round of Financing

By StartUp City | Friday, March 20, 2020

The funding will drive the first-in-human clinical trial of Sigilon's novel encapsulated cell therapy for hemophilia A, which is expected to begin in the first half of 2020. It will also support the continued advancement and expansion of Sigilon's programs in rare blood disorders, lysosomal diseases, and endocrine and immune disorders.

FREMONT, CA: Sigilon Therapeutics, a biotechnology firm pioneering functional cures for patients with chronic diseases through its Shielded Living Therapeutics platform, secured $80.3 million in Series B Round of Financing.

Canada Pension Plan Investment Board (CPP Investments), Longevity Vision Fund and funds managed by BlackRock joined founding investor Flagship Pioneering and existing investors, including Eli Lilly and Company, in the financing round. Sigilon has raised more than $195 million to date.

The funding will drive the first-in-human clinical trial of Sigilon's novel encapsulated cell therapy for hemophilia A, which is expected to begin in the first half of 2020. It will also support the continued advancement and expansion of Sigilon's programs in rare blood disorders, lysosomal diseases, and endocrine and immune disorders.

Rogerio Vivaldi, M.D., President and CEO of Sigilon, said, "Sigilon is driven to liberate patients from the fear of living with serious chronic diseases, and from alternative therapeutic approaches. Our Shielded Living Therapeutics platform is designed to give patients who have chronic diseases a convenient, safe, long-term therapeutic benefit. We believe encapsulating engineered human cells in our proprietary matrix will enable us to deliver controlled doses of therapeutic proteins without the need for immunosuppression and without the risks associated with modifying patients' genomes. We are pleased to welcome an exceptional group of investors who share our vision of offering more hope and less fear to patients and their caregivers as we enter the clinic with our lead program and continue to advance our other programs toward the clinic."

Douglas Cole, M.D., Managing Partner at Flagship Pioneering and Chairman of the Board at Sigilon, stated, "Sigilon's Shielded Living Therapeutics platform offers patients with chronic disease the prospect of relief without disrupting their lives. The near-term transition to clinical development and the platform's breadth and progress reflect the power and productivity of Sigilon's approach. Successful conclusion of this financing puts the company in a strong position to build further value."

15 Most Promising Customer Services Startups - 2019Sigilon was established to develop bio-engineered, immune-protected cells to restore normal physiology in various diseases without immune rejection, freeing patients from the challenges associated with existing treatments for serious chronic diseases. Treatments based on Sigilon's Shielded Living Therapeutics platform combine advanced cell engineering with advanced innovations in biocompatible materials to develop a new class of medicines that have been designed to provide redosable, durable, controllable and safe potential treatment for chronic diseases.

Sigilon's lead investigational therapy for hemophilia A, SIG-001, received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA). Sigilon plans to begin a clinical trial of SIG-001 in the first half of 2020.

See Also: Top FinTech Consulting/Service Companies

Weekly Brief